Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:41:01.400Z.
Calculation as of: 2026-10-06T15:41:01.400Z.
Quote observation: 2026-10-06T15:38:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3c83d1468e5e3921618bd37e367f41e2e7287b0e28e44d51d30477b87a45d5ec
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Baird Medical Investment Holdings Limited
Market Cap
$31.70M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$31.77M
Price/FCF Ratio
16.44
TTM Avg
17.64
3Y Avg
23.73
5Y Avg
19.18
Market Cap
$31.37M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$32.76M
Price/FCF Ratio
N/A
TTM Avg
507.99
3Y Avg
507.99
5Y Avg
507.99
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Baird Medical Investment Holdings Limited (BDMD) | $31.70M | N/A | N/A | N/A | N/A |
| BeyondSpring Inc. (BYSI)vs › | $30.84M | N/A | N/A | N/A | N/A |
| MDxHealth S.A. (MDXH)vs › | $30.96M | N/A | N/A | N/A | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $31.59M | N/A | N/A | N/A | N/A |
| Nortech Systems Incorporated (NSYS)vs › | $31.77M | 16.44 | 17.64 | 23.73 | 19.18 |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $31.37M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $32.76M | N/A | 507.99 | 507.99 | 507.99 |
| CervoMed Inc. (CRVO)vs › | $29.68M | N/A | N/A | N/A | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $30.27M | N/A | N/A | N/A | N/A |
| Quantum Cyber N.V. (QUCY)vs › | $29.71M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
